Component

Human diabetic-neuropathy pain score

Human diabetic-neuropathy pain score

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Pain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.

    Acetyl-L-carnitine → Human diabetic-neuropathy pain score Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    experimental_contrast
    {"intervention": "ALCAR regimen", "comparator": "Placebo", "endpoint": "Pain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily.
    interpretation_status
    Source-derived curation with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
    plain_language
    Pain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.
    primary_references
    Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. | https://pubmed.ncbi.nlm.nih.gov/15616239/ | https://doi.org/10.2337/diacare.28.1.89
    source_locator
    Reviewed reference dpn05-pain; Pain was assessed in participants for whom it was the most bothersome symptom. This is not consistent benefit in every randomized participant.

    Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 499–505

    AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily. · Recorded from source · Recorded from source

    ### dpn05-pain Pain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses. Pain was assessed in participants for whom it was the most bothersome symptom. This is not consistent benefit in every randomized participant. Model and exposure: Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. | 2005 | https://pubmed.ncbi.nlm.nih.gov/15616239/ | https://doi.org/10.2337/diacare.28.1.89 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    Complete structured claim and evidence

  2. The 24-week foot-pain component did not reach statistical significance in the 2024 ALCAR trial.

    Acetyl-L-carnitine → Human diabetic-neuropathy pain score Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "ALCAR hydrochloride for 24 weeks", "comparator": "Placebo", "endpoint": "The 24-week foot-pain component did not reach statistical significance in the 2024 ALCAR trial.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Same trial; component analysis P=0.066.
    interpretation_status
    Source-derived curation with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
    plain_language
    The 24-week foot-pain component did not reach statistical significance in the 2024 ALCAR trial.
    primary_references
    Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377
    source_locator
    Reviewed reference dpn24-pain-null; More than half of participants had baseline numeric pain scores of 0–1. A composite neuropathy benefit is not automatically a demonstrated analgesic effect.

    Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 523–529

    AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Same trial; component analysis P=0.066. · Recorded from source · Recorded from source

    ### dpn24-pain-null The 24-week foot-pain component did not reach statistical significance in the 2024 ALCAR trial. More than half of participants had baseline numeric pain scores of 0–1. A composite neuropathy benefit is not automatically a demonstrated analgesic effect. Model and exposure: Same trial; component analysis P=0.066. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.